June 4, 2021
Over 80 percent of non-small cell lung cancer detected at Stage 4 Fewer than 50 percent of patients had five or more biomarker tests Median time from diagnosis to first-line therapy is about five weeks THE WOODLANDS, TEXAS, June 4, 2021 — Results from the first phase of the broad, collaborative MYLUNG ConsortiumTM research study […]
Read MoreJune 3, 2021
Key highlights include a plenary session on cervical cancer among women in developing nations and an oral abstract exploring molecular testing and targeted therapy for metastatic non-small cell lung cancer, among other topics THE WOODLANDS, Texas, June 3, 2021 — US Oncology Research, The US Oncology Network (The Network), and OntadaTM announce they contributed to […]
Read MoreApril 1, 2021
By joining The Network, these physicians contribute to the expansion of colorectal services in Texas THE WOODLANDS, Texas, April 1, 2021—The US Oncology Network (The Network), the largest organization of its kind dedicated to advancing local cancer care and better patient outcomes, continues to expand its reach into local communities while broadening its surgical expertise […]
Read MoreMarch 25, 2021
Eight custom measures receive approval, raising the bar on oncology patient care IRVING, Texas, March 25, 2021 — For the fifth consecutive year, McKesson has received approval from The Centers for Medicare & Medicaid Services (CMS) to participate in the Merit-based Incentive Payment System (MIPS) as a Qualified Clinical Data Registry (QCDR). As a CMS-approved QCDR, Practice Insights, a […]
Read MoreFebruary 4, 2021
Unique, collaborative real-world research consortium will study up to 12,000 NSCLC patients in the community setting over five years MYLUNG to deepen understanding of barriers and address challenges to improve care for lung cancer patients, including those with targetable mutations The MYLUNG consortium – or “Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: […]
Read MoreDecember 2, 2020
Top researchers to present the latest clinical findings advancing treatment options for blood cancers and other hematologic diseases THE WOODLANDS, Texas, Dec. 2, 2020 — During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, principal investigators from The US Oncology Network (The Network) and US Oncology Research will share detailed results from […]
Read MoreNovember 11, 2020
Community-based practices in The Network advance value-based care by significantly reducing costs while enhancing care THE WOODLANDS, TEXAS, Nov. 11, 2020—The US Oncology Network (The Network) reached a major milestone recently in its journey to provide high-quality, value-based care to local communities by enrolling its 100,000th patient in the Centers for Medicare & Medicaid Innovation’s […]
Read MoreOctober 22, 2020
By uniting with The Network, Alliance Cancer Specialists and Northwest Oncology strengthen their ability to deliver advanced cancer care in local communities THE WOODLANDS, Texas, Oct. 22, 2020— The US Oncology Network (The Network), the largest organization of its kind dedicated to advancing local cancer care and better patient outcomes, continues to expand its reach […]
Read MoreOctober 6, 2020
Chief Scientific Officer of US Oncology Research honored for groundbreaking achievements in gynecologic oncology THE WOODLANDS, Texas, Oct. 6, 2020 — Robert L. Coleman, MD, FACOG, FACS, chief scientific officer of US Oncology Research, has been named an inductee to the 2020 class of the OncLive® Giants of Cancer Care®. Now in its eighth year, […]
Read MoreSeptember 30, 2020
Inclusion of the CRESTONE Study within the Selected Trials for Accelerated Rollout Program will enhance patient recruitment and facilitate local site participation for patients with tumors harboring an NRG1 Gene Fusion NEW YORK, NY and THE WOODLANDS, Texas, Sept. 30, 2020—Elevation Oncology, a clinical stage biopharmaceutical company focused on the development of precision medicines for […]
Read More
